Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Aerosolized Amikacin (NKTR-061) in Intubated Patients with Pneumonia
NCT01021436Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2007
- Primary completion
- Aug 2007
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of amikacin liposome inhalation suspension in hospital-acquired pneumonia (HAP), sponsored by Bayer. Started Mar 2007; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT01021436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01021436.